Economic Evaluation of Human Rotavirus Vaccine in Thailand

ConclusionHRV vaccination is estimated to be cost-effective in Thailand. The budget impact following inclusion of HRV into the UMV programme is expected to be partially offset by substantial reductions in RV-related disease costs.FundingGlaxoSmithKline Biologicals SAGSK Study IdentifierHO-17-18213
Source: Infectious Diseases and Therapy - Category: Infectious Diseases Source Type: research